3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
5
Terminated
2
Unknown
1
Recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
21
Thoracic
3
Sarcoma
2
NET
2
Lymphoid
2
Head & Neck
2
Endocrine
2
Dermatologic
2
Breast
2
Gynecologic
1
Genitourinary
1
CNS
1
Conditions
Breast Neoplasms
1127
Triple Negative Breast Neoplasms
146
Neoplasm Metastasis
99
Carcinoma, Non-Small-Cell Lung
85
Ovarian Neoplasms
81
Neoplasms
74
Lung Neoplasms
64
Colorectal Neoplasms
60
Melanoma
58
Stomach Neoplasms
44
Pancreatic Neoplasms
43
Breast Neoplasms, Male
43
Prostatic Neoplasms
42
Carcinoma, Renal Cell
37
Squamous Cell Carcinoma of Head and Neck
34
Sarcoma
30
Colonic Neoplasms
29
Endometrial Neoplasms
28
Head and Neck Neoplasms
26
Brain Neoplasms
24
Urinary Bladder Neoplasms
22
Esophageal Neoplasms
21
Carcinoma, Ovarian Epithelial
21
Carcinoma, Intraductal, Noninfiltrating
21
Lymphoma, Non-Hodgkin
19
Recurrence
18
Uterine Cervical Neoplasms
17
Inflammatory Breast Neoplasms
17
Breast Carcinoma In Situ
17
Multiple Myeloma
16
Interventions
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Digestive System Neoplasms
×
Breast
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts
NCT02602067
2018-09-18
Tenatumomab
sigma-tau i.f.r. S.p.A.
Phase 1
Terminated
2 enrolled